Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Takuo Yamai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5448-4763; OpenAlex author ID A5053643525. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers · 2025: none · 2026: 2 papers

Papers 20

  1. Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic C… Co-author DOI 10.1002/cnr2.70691↗
  2. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  3. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. Co-author DOI 10.1007/s10147-024-02544-w↗
  4. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-024-73020-8↗
  5. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. First author DOI 10.1186/s12885-024-12722-8↗
  6. Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. Co-author DOI 10.1007/s00432-023-04966-x↗
  7. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. Co-author DOI 10.1186/s12885-023-11205-6↗
  8. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Co-author DOI 10.3390/cancers15030970↗
  9. Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Co-author DOI 10.1016/j.jgo.2022.07.010↗
  10. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  11. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002152↗
  12. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Co-author DOI 10.1371/journal.pone.0264653↗
  13. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Co-author DOI 10.3390/curroncol29040216↗
  14. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Co-author DOI 10.1002/jgh3.12555↗
  15. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  16. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗
  17. Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions. Co-author DOI 10.1097/mpa.0000000000001521↗
  18. Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001652↗
  19. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels. Co-author DOI 10.1371/journal.pone.0235573↗
  20. Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1. Co-author DOI 10.1159/000364819↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Ikezawa · 17 shared papers, 2020–2026 · strength 2.51
  2. Ryoji Takada · 17 shared papers, 2014–2026 · strength 2.45
  3. Kazuyoshi Ohkawa · 16 shared papers, 2020–2026 · strength 2.41
  4. Yugo Kai · 14 shared papers, 2021–2026 · strength 2.20
  5. Makiko Urabe · 12 shared papers, 2020–2026 · strength 1.90
  6. Nobuyasu Fukutake · 8 shared papers, 2014–2026 · strength 1.01
  7. Yasuharu Kawamoto · 6 shared papers, 2022–2024 · strength 0.92
  8. Ko Watsuji · 5 shared papers, 2023–2024 · strength 0.85
  9. Yusuke Seiki · 5 shared papers, 2023–2024 · strength 0.85
  10. Kazuma Daiku · 6 shared papers, 2021–2022 · strength 0.79
  11. Reiko Ashida · 5 shared papers, 2014–2021 · strength 0.46
  12. Shigenori Nagata · 3 shared papers, 2021–2024 · strength 0.42
  13. Hidenori Takahashi · 3 shared papers, 2021–2022 · strength 0.34
  14. Kazuhiro Katayama · 3 shared papers, 2020–2021 · strength 0.32
  15. Yoji Kukita · 2 shared papers, 2020–2023 · strength 0.24
  16. Akiko Tsujimoto · 1 shared paper, 2026 · strength 0.20
  17. Koh Kitagawa · 1 shared paper, 2026 · strength 0.20
  18. Yuki Ishikawa‐Kakiya · 1 shared paper, 2026 · strength 0.20
  19. Mamoru Takenaka · 1 shared paper, 2026 · strength 0.20
  20. Tsukasa Ikeura · 1 shared paper, 2026 · strength 0.20
  21. Tomoya Emori · 1 shared paper, 2026 · strength 0.20
  22. Yoshihiro Nishikawa · 1 shared paper, 2026 · strength 0.20
  23. Tomoaki Matsumori · 1 shared paper, 2026 · strength 0.20
  24. Atsuhiro Masuda · 1 shared paper, 2026 · strength 0.20
  25. Takashi Ito · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.